SAN Sanofi

Form 8.3 - The Vanguard Group, Inc.: Sanofi

The Vanguard Group, Inc. ( IRSH)
Form 8.3 - The Vanguard Group, Inc.: Sanofi

01-Dec-2022 / 15:09 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Ap19

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY INFORMATION

 

Name of person dealing (Note 1)

The Vanguard Group, Inc.

Company dealt in

Sanofi

Class of relevant security to which the dealings being disclosed relate (Note 2)

Ordinary Shares

Date of dealing

29 November 2022

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

41,259,671

3.26%

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

41,259,671

3.26%

 

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

 

 

Ap20

 

1.  Dealings (Note 4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

 

 

 

 

 

(b)  Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Not Applicable

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

(i)  Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Not Applicable

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

Not Applicable

 

 

 

 

(e)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Not Applicable

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                           NO

 

Date of disclosure

01 December 2022

Contact name

Shawn Acker

Telephone number

001-610-669-8989

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 



Category Code: RET - Sanofi
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 205631
EQS News ID: 1503367

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1503367&application_name=news&site_id=research_pool
EN
01/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi commits an additional $625 million to Sanofi Ven...

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategySanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering hea...

 PRESS RELEASE

Communiqué de presse : Sanofi engage 625 millions de dollars supplémen...

Communiqué de presse : Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique Le fonds restera axé sur les domaines clés de Sanofi que sont l’immunologie, les maladies rares, la neurologie et les vaccins, en appuyant l’innovation en amont et les opportunités émergentes qui soutien...

 PRESS RELEASE

Press release: Availability of the Q3 2025 Aide mémoire

Press release: Availability of the Q3 2025 Aide mémoire   Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on October 24, 2025.    About ...

 PRESS RELEASE

Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire...

Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire" Mise en ligne du document «Q3 2025 Aide mémoire » Paris, France, le 24 septembre 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier trime...

 PRESS RELEASE

Press Release: Sanofi’s SAR446268 earns US fast track designation for ...

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expressionMyotonic dystrophy type 1 (DM1) is a rare, genetic disorder that causes progressive muscle weakness and wasting, with no currently approved medicines Paris, September 23, 2025. The US Food and Drug Administration (FDA) has granted fast track designation t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch